Chaohong He
4 Papers
Chaohong He is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.
Zibing Wang,Yong Zhang,Yuqing Liu,Li Wang,Lingdi Zhao,Tiejun Yang,Chaohong He,Yongping Song,Quanli Gao +8 more
TL;DR: The data suggest that transfusion of autologous CIK cells can induce regression of MRCC, and MDSCs can serve as a potential marker for the prognosis of patients receiving a CIK-based therapy.
45
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
Yuan-Yuan Qu,Zhongquan Sun,Weiqing Han,Qing Zou,Nianzeng Xing,Hong Luo,Xuepei Zhang,Chaohong He,Xiaojie Bian,Jinling Cai,Chunxia Chen,Quanren Wang,Dingwei Ye +12 more
TL;DR: Camrelizumab plus famitinib showed potent antitumor activity in advanced or metastatic urothelial carcinoma patients after platinum-based chemotherapy, and patients with bladder cancer seemed to have better response to this combination.
Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial
Xiao Jian Qin,Dongmei Ji,Weijie Gu,Weiqing Han,Hong Luo,Chuanjun Du,Qing Zou,Zhongquan Sun,Chaohong He,Shaoxin Zhu,Tie Chong,Xin Yao,B. Wang,Xinfeng Yang,A. Bai,Chunlei Jin,Jianjun Zou,Dingwei Ye +17 more
TL;DR: In this paper , the safety, pharmacokinetics, and activity of SHR3680 (a novel AR antagonist) in patients with metastatic castration-resistant prostate cancer (CRPC) were evaluated.
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
Xinan Sheng,Dingwei Ye,Aiping Zhou,Xin Yao,Hong Luo,Zhisong He,Zengjun Wang,Ying Zhao,Zhigang Ji,Qing Zou,Chaohong He,Jianming Guo,Xinhua Tu,Ziling Liu,Benkang Shi,Ben Liu,Peng Chen,Qiang Wei,Zhiquan Hu,Yanqiao Zhang,Kui Jiang,Fangjian Zhou,Dapeng Wu,Cheng Fu,Xing-Ya Li,Bin Wu,Lijie Wang,Shukui Qin,Gangguo Li,Yunpeng Liu,Hongqian Guo,Ke-he Chen,Dahong Zhang,Gongxian Wang,Lieming Ding,Yangbin Wang,M.M. Xiaobin Yuan,Jun Guo +37 more
TL;DR: In this paper , a three-arm, randomised, registered study aimed to assess the combination of vorolanib and everolimus versus a control arm of everolmus as second-line treatment in patients with metastatic renal cell carcinoma (RCC).